Cargando…
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and di...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796592/ https://www.ncbi.nlm.nih.gov/pubmed/31492560 http://dx.doi.org/10.1016/j.ebiom.2019.08.055 |
_version_ | 1783459640235786240 |
---|---|
author | Yu, Yu Suryo Rahmanto, Yohan Shen, Yao-An Ardighieri, Laura Davidson, Ben Gaillard, Stephanie Ayhan, Ayse Shi, Xu Xuan, Jianhua Wang, Tian-Li Shih, Ie-Ming |
author_facet | Yu, Yu Suryo Rahmanto, Yohan Shen, Yao-An Ardighieri, Laura Davidson, Ben Gaillard, Stephanie Ayhan, Ayse Shi, Xu Xuan, Jianhua Wang, Tian-Li Shih, Ie-Ming |
author_sort | Yu, Yu |
collection | PubMed |
description | BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and directly enhances their phosphorylation. METHODS: We used immunohistochemistry and immunoblotting to assess SYK and EGFR phosphorylation in ovarian serous carcinomas. Association with survival was determined by Kaplan-Meier analysis and the log-rank test. To study its role in EGFR signaling, SYK activity was modulated using a small molecule inhibitor, a syngeneic knockout, and an active kinase inducible system. We applied RNA-seq and phosphoproteomic mass spectrometry to investigate the SYK-regulated EGF-induced transcriptome and downstream substrates. FINDINGS: Induced expression of constitutively active SYK(130E) reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib. Expression of EGFR(WT), but not SYK non-phosphorylatable EGFR(3F) mutant, resulted in paclitaxel resistance, a phenotype characteristic to SYK active ovarian cancers. In tumor xenografts, SYK inhibitor reduces phosphorylation of EGFR substrates. Compared to SYK(WT) cells, SYK(KO) cells have an attenuated EGFR/ERBB2-transcriptional activity and responsiveness to EGF-induced transcription. In ovarian cancer tissues, pSYK (Y525/526) levels showed a positive correlation with pEGFR (Y1187). Intense immunoreactivity of pSYK (Y525/526) correlated with poor overall survival in ovarian cancer patients. INTERPRETATION: These findings indicate that SYK activity positively modulates the EGFR pathway, providing a biological foundation for co-targeting SYK and EGFR. FUND: Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, NIH/NCI, Ovarian Cancer Research Foundation Alliance, HERA Women's Cancer Foundation and Roseman Foundation. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript and eventually in the decision to submit the manuscript. |
format | Online Article Text |
id | pubmed-6796592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-67965922019-10-22 Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer Yu, Yu Suryo Rahmanto, Yohan Shen, Yao-An Ardighieri, Laura Davidson, Ben Gaillard, Stephanie Ayhan, Ayse Shi, Xu Xuan, Jianhua Wang, Tian-Li Shih, Ie-Ming EBioMedicine Research paper BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and directly enhances their phosphorylation. METHODS: We used immunohistochemistry and immunoblotting to assess SYK and EGFR phosphorylation in ovarian serous carcinomas. Association with survival was determined by Kaplan-Meier analysis and the log-rank test. To study its role in EGFR signaling, SYK activity was modulated using a small molecule inhibitor, a syngeneic knockout, and an active kinase inducible system. We applied RNA-seq and phosphoproteomic mass spectrometry to investigate the SYK-regulated EGF-induced transcriptome and downstream substrates. FINDINGS: Induced expression of constitutively active SYK(130E) reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib. Expression of EGFR(WT), but not SYK non-phosphorylatable EGFR(3F) mutant, resulted in paclitaxel resistance, a phenotype characteristic to SYK active ovarian cancers. In tumor xenografts, SYK inhibitor reduces phosphorylation of EGFR substrates. Compared to SYK(WT) cells, SYK(KO) cells have an attenuated EGFR/ERBB2-transcriptional activity and responsiveness to EGF-induced transcription. In ovarian cancer tissues, pSYK (Y525/526) levels showed a positive correlation with pEGFR (Y1187). Intense immunoreactivity of pSYK (Y525/526) correlated with poor overall survival in ovarian cancer patients. INTERPRETATION: These findings indicate that SYK activity positively modulates the EGFR pathway, providing a biological foundation for co-targeting SYK and EGFR. FUND: Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, NIH/NCI, Ovarian Cancer Research Foundation Alliance, HERA Women's Cancer Foundation and Roseman Foundation. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript and eventually in the decision to submit the manuscript. Elsevier 2019-09-03 /pmc/articles/PMC6796592/ /pubmed/31492560 http://dx.doi.org/10.1016/j.ebiom.2019.08.055 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Yu, Yu Suryo Rahmanto, Yohan Shen, Yao-An Ardighieri, Laura Davidson, Ben Gaillard, Stephanie Ayhan, Ayse Shi, Xu Xuan, Jianhua Wang, Tian-Li Shih, Ie-Ming Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title | Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title_full | Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title_fullStr | Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title_full_unstemmed | Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title_short | Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
title_sort | spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796592/ https://www.ncbi.nlm.nih.gov/pubmed/31492560 http://dx.doi.org/10.1016/j.ebiom.2019.08.055 |
work_keys_str_mv | AT yuyu spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT suryorahmantoyohan spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT shenyaoan spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT ardighierilaura spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT davidsonben spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT gaillardstephanie spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT ayhanayse spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT shixu spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT xuanjianhua spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT wangtianli spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer AT shihieming spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer |